BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 20809023)

  • 1. The study of p53 and CA19-9 prognostic molecular markers in colorectal carcinomas.
    Afrem G; Crăiţoiu S; Mărgăritescu C; Mogoantă SS
    Rom J Morphol Embryol; 2010; 51(3):473-81. PubMed ID: 20809023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunohistochemical study of P53 protein on colorectal carcinomas.
    Pandrea IV; Mihailovici MS; Carasevici E; Székely AM; Reynes M; Târcoveanu E; Dragomir C
    Rev Med Chir Soc Med Nat Iasi; 1995; 99(3-4):171-8. PubMed ID: 9455363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunohistochemical detection of p53 in colorectal cancer and its relationship to prognosis].
    Yamaguchi A; Fushida S; Kurosaka Y; Kanno M; Yonemura Y; Miyazaki I
    Nihon Geka Gakkai Zasshi; 1992 Oct; 93(10):1312-6. PubMed ID: 1435694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
    Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
    Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis is a new promising prognostic factor in colorectal cancer.
    Pollheimer MJ; Kornprat P; Lindtner RA; Harbaum L; Schlemmer A; Rehak P; Langner C
    Hum Pathol; 2010 Dec; 41(12):1749-57. PubMed ID: 20869096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations of proliferation markers, p53 expression and histological findings in colorectal carcinoma.
    Georgescu CV; Săftoiu A; Georgescu CC; Ciurea R; Ciurea T
    J Gastrointestin Liver Dis; 2007 Jun; 16(2):133-9. PubMed ID: 17592558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
    Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A
    Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E
    Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas.
    Diez M; Medrano M; Mugüerza JM; Ramos P; Hernandez P; Villeta R; Martín A; Noguerales F; Ruiz A; Granell J
    Anticancer Res; 2000; 20(5C):3907-12. PubMed ID: 11268475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance.
    Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
    Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunohistochemical distribution of p53 and Ki-67 in 2 cases of colorectal carcinoma occurring in ulcerative colitis].
    Maruyama K; Saigusa N; Baba S; Kino I
    Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():145-8. PubMed ID: 7611778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance.
    Baretton GB; Diebold J; Christoforis G; Vogt M; Müller C; Dopfer K; Schneiderbanger K; Schmidt M; Löhrs U
    Cancer; 1996 Jan; 77(2):255-64. PubMed ID: 8625232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor markers in staging and prognosis of colorectal carcinoma.
    Levy M; Visokai V; Lipska L; Topolcan O
    Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
    Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
    Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy.
    Kawahira H; Kobayashi S; Kaneko K; Asano T; Ochiai T
    Hepatogastroenterology; 2000; 47(34):973-7. PubMed ID: 11020860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.